LMAT · Lemaitre Vascular Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $249.60M | $219.86M | $193.48M | $161.65M | $154.42M | $129.37M |
| Cost of Revenue | $71.06M | $68.96M | $66.44M | $56.76M | $53.04M | $44.75M |
| Gross Profit | $178.54M | $150.90M | $127.05M | $104.90M | $101.38M | $84.62M |
| R&D | $14.14M | $15.65M | $16.97M | $13.29M | $11.80M | $10.10M |
| SG&A | $42.02M | $36.26M | $31.83M | $28.75M | $25.50M | $22.50M |
| Total Operating Expenses | $110.63M | $98.64M | $90.34M | $78.07M | $64.96M | $55.83M |
| D&A | $10.42M | $9.67M | $9.52M | $9.43M | $11.07M | $8.39M |
| Operating Income | $67.91M | $52.26M | $36.71M | $26.83M | $36.42M | $28.79M |
| Interest Expense | $5.18M | $205.0K | $0 | $0 | $2.22M | $1.31M |
| Income Tax | $17.45M | $12.84M | $9.37M | $6.85M | $7.38M | $6.14M |
| Net Income | $57.73M | $44.04M | $30.11M | $20.64M | $26.91M | $21.22M |
| EPS - Basic | $2.55 | $1.96 | $1.36 | $0.94 | $1.27 | $1.05 |
| EPS - Diluted | $2.52 | $1.93 | $1.34 | $0.93 | $1.25 | $1.04 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $28.24M | $25.61M | $24.27M | $19.13M | $13.86M | $26.76M |
| Accounts Receivable | $33.61M | $30.06M | $25.06M | $22.04M | $19.63M | $19.55M |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $3.65M | $1.76M | $3.73M | $2.90M | $2.34M | $2.39M |
| Current Assets | $468.23M | $402.19M | $194.60M | $161.73M | $139.88M | $94.26M |
| Total Assets | $615.69M | $551.82M | $346.78M | $310.48M | $292.80M | $252.81M |
| Current Liabilities | $36.32M | $30.61M | $29.88M | $25.33M | $21.81M | $25.14M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $222.17M | $214.53M | $48.88M | $42.27M | $38.65M | $80.24M |
| Stockholders' Equity | $393.52M | $337.29M | $297.90M | $268.20M | $254.15M | $172.57M |
| Retained Earnings | $184.72M | $145.09M | $115.43M | $97.77M | $88.13M | $70.55M |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $81.25M | $44.12M | $36.75M | $25.38M | $35.10M | $34.80M |
| Investing Cash Flow | ($64.94M) | ($200.12M) | ($24.71M) | ($10.37M) | ($61.08M) | ($52.89M) |
| Financing Cash Flow | ($14.54M) | $158.10M | ($7.13M) | ($9.23M) | $13.70M | $32.16M |
| CapEx | $6.78M | $6.96M | $7.26M | $3.23M | $4.88M | $2.98M |
| Free Cash Flow | $74.47M | $37.16M | $29.49M | $22.15M | $30.22M | $31.82M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 71.5% | 68.6% | 65.7% | 64.9% | 65.7% | 65.4% |
| Operating margin | 27.2% | 23.8% | 19.0% | 16.6% | 23.6% | 22.3% |
| EBITDA margin | 31.4% | 28.2% | 23.9% | 22.4% | 30.8% | 28.7% |
| Net margin | 23.1% | 20.0% | 15.6% | 12.8% | 17.4% | 16.4% |
| Free cash flow margin | 29.8% | 16.9% | 15.2% | 13.7% | 19.6% | 24.6% |
| FCF / Net income | 1.29 | 0.84 | 0.98 | 1.07 | 1.12 | 1.50 |
| R&D / Revenue | 5.7% | 7.1% | 8.8% | 8.2% | 7.6% | 7.8% |
| SG&A / Revenue | 16.8% | 16.5% | 16.5% | 17.8% | 16.5% | 17.4% |
| Effective tax rate | 23.2% | 22.6% | 23.7% | 24.9% | 21.5% | 22.4% |
| Return on assets | 9.4% | 8.0% | 8.7% | 6.6% | 9.2% | 8.4% |
| Return on equity | 14.7% | 13.1% | 10.1% | 7.7% | 10.6% | 12.3% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 12.89 | 13.14 | 6.51 | 6.39 | 6.41 | 3.75 |
| Quick ratio | 12.89 | 13.14 | 6.51 | 6.39 | 6.41 | 3.75 |
| Cash ratio | 0.78 | 0.84 | 0.81 | 0.76 | 0.64 | 1.06 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | 13.1x | 254.9x | - | - | 16.4x | 22.0x |
| Equity multiplier | 1.56 | 1.64 | 1.16 | 1.16 | 1.15 | 1.46 |
| Liabilities / Assets | 0.36 | 0.39 | 0.14 | 0.14 | 0.13 | 0.32 |
| Efficiency | ||||||
| Asset turnover | 0.41 | 0.40 | 0.56 | 0.52 | 0.53 | 0.51 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 49d | 50d | 47d | 50d | 46d | 55d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | 19d | 9d | 21d | 19d | 16d | 20d |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | 32.2x | 47.7x | 42.4x | 49.5x | 40.2x | 38.9x |
| P / B | 4.7x | 6.2x | 4.3x | 3.8x | 4.2x | 4.8x |
| P / S | 7.5x | 9.5x | 6.6x | 6.3x | 7.0x | 6.4x |
| EV / EBITDA | 23.4x | 33.5x | 27.0x | 27.6x | 22.4x | 21.6x |
| Growth | ||||||
| Revenue growth (YoY) | 13.5% | 13.6% | 19.7% | 4.7% | 19.4% | 10.4% |
| Revenue CAGR (3y) | 15.6% | 12.5% | 14.4% | 11.3% | 15.3% | 8.6% |
| Revenue CAGR (5y) | 14.0% | 13.4% | 13.9% | 9.9% | 11.6% | 10.5% |
| Gross profit growth (YoY) | 18.3% | 18.8% | 21.1% | 3.5% | 19.8% | 6.0% |
| Operating income growth (YoY) | 30.0% | 42.3% | 36.8% | -26.3% | 26.5% | 35.9% |
| Net income growth (YoY) | 31.1% | 46.3% | 45.9% | -23.3% | 26.8% | 18.3% |
| EPS growth (YoY) | 30.6% | 44.0% | 44.1% | -25.6% | 20.2% | 18.2% |
| EPS CAGR (3y) | 39.4% | 15.6% | 8.8% | 1.9% | 3.4% | 6.5% |
| EPS CAGR (5y) | 19.4% | 17.0% | 3.5% | 1.6% | 17.8% | 19.9% |
| FCF growth (YoY) | 100.4% | 26.0% | 33.1% | -26.7% | -5.0% | 205.4% |
| FCF CAGR (5y) | 18.5% | 29.0% | 16.3% | 2.0% | 16.5% | 28.3% |
| Book value growth (YoY) | 16.7% | 13.2% | 11.1% | 5.5% | 47.3% | 16.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Geographic
$249.60M totalAmericas$159.66M · 64.0%
EMEA$73.12M · 29.3%
Asia Pacific$16.82M · 6.7%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
2.25
Grey zone
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
7/9
Strong
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing LEMAITRE VASCULAR INC against the 5 most active filers in the same SIC group.
Dividends
$0.90/share trailing 12 months · +25.0% YoY
| Ex-date | Per share |
|---|---|
| May 21, 2026 | $0.2500 |
| Mar 12, 2026 | $0.2500 |
| Nov 20, 2025 | $0.2000 |
| Aug 21, 2025 | $0.2000 |
| May 15, 2025 | $0.2000 |
| Mar 13, 2025 | $0.2000 |
| Nov 21, 2024 | $0.1600 |
| Aug 15, 2024 | $0.1600 |
| May 15, 2024 | $0.1600 |
| Mar 13, 2024 | $0.1600 |
| Nov 15, 2023 | $0.1400 |
| Aug 16, 2023 | $0.1400 |
| May 16, 2023 | $0.1400 |
| Mar 8, 2023 | $0.1400 |
| Nov 16, 2022 | $0.1250 |
| Aug 24, 2022 | $0.1250 |
| May 16, 2022 | $0.1250 |
| Mar 7, 2022 | $0.1250 |
| Nov 18, 2021 | $0.1100 |
| Aug 25, 2021 | $0.1100 |
| May 18, 2021 | $0.1100 |
| Mar 8, 2021 | $0.1100 |
| Nov 18, 2020 | $0.0950 |
| Aug 26, 2020 | $0.0950 |